Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	174.77	37.8	39.55	298.17	89.96	81.47
Short-Term Investments	154.91	50.55	62.88	29.31	83.51	211.47
Cash & Short-Term Investments	329.68	88.35	102.43	327.48	173.47	292.94
Cash Growth	260.85%	-13.74%	-68.72%	88.79%	-40.78%	4.31%
Accounts Receivable	18.27	18.44	17.47	16.79	14.07	15.87
Other Receivables	-	50	-	-	-	53.8
Receivables	18.27	68.44	17.47	16.79	14.07	69.67
Prepaid Expenses	6.75	4.28	13.64	9.2	18.81	30.73
Other Current Assets	-	-	-	-	43.53	-
Total Current Assets	354.7	161.07	133.54	353.46	249.87	393.34
Property, Plant & Equipment	31.71	35.77	45.36	52	53.35	59.68
Long-Term Investments	3.03	-	-	-	-	12.75
Other Long-Term Assets	26.03	157.32	203.1	201.94	71.6	3.28
Total Assets	415.46	354.16	382	607.4	374.82	469.06
Accounts Payable	2.21	2.24	1.52	1.55	3.1	6.78
Accrued Expenses	20.21	13.28	12.83	20.41	37.95	76.07
Current Portion of Long-Term Debt	-	-	-	-	16.94	19.33
Current Portion of Leases	10.91	10.71	3.92	6.75	0.5	9.87
Current Income Taxes Payable	4.07	5.85	-	-	-	-
Current Unearned Revenue	-	-	-	-	0.1	11.52
Other Current Liabilities	-	-	6.49	-	-	-
Total Current Liabilities	37.41	32.09	24.77	28.72	58.59	123.57
Long-Term Debt	-	-	-	-	599.39	599.84
Long-Term Leases	33.68	39.11	45.24	45.41	52.68	47.22
Long-Term Unearned Revenue	-	-	-	0.19	0.31	0.35
Other Long-Term Liabilities	111.69	107.42	99	91.29	2.42	1.83
Total Liabilities	182.78	178.62	169	165.6	713.39	772.81
Common Stock	0	-	-	0	0	0
Additional Paid-In Capital	1,153	1,141	1,122	1,296	1,387	1,223
Retained Earnings	-920.65	-965.52	-909.1	-853.91	-1,726	-1,527
Comprehensive Income & Other	0.03	0.01	-0.07	-0.02	-	0.05
Shareholders' Equity	232.68	175.55	213	441.8	-338.57	-303.75
Total Liabilities & Equity	415.46	354.16	382	607.4	374.82	469.06
Total Debt	44.6	49.82	49.16	52.16	669.52	676.26
Net Cash (Debt)	288.11	38.53	53.27	275.32	-496.05	-383.32
Net Cash Growth	521.20%	-27.67%	-80.65%	-	-	-
Net Cash Per Share	5.70	0.79	0.96	3.74	-7.14	-6.15
Filing Date Shares Outstanding	50.67	49.47	48.16	62.86	74.7	64.33
Total Common Shares Outstanding	50.67	49.47	48.09	65.23	74.44	64.33
Working Capital	317.29	128.98	108.77	324.75	191.28	269.77
Book Value Per Share	4.59	3.55	4.43	6.77	-4.55	-4.72
Tangible Book Value	232.68	175.55	213	441.8	-338.57	-303.75
Tangible Book Value Per Share	4.59	3.55	4.43	6.77	-4.55	-4.72
Machinery	-	3.74	3.68	19.04	26.03	35.88
Leasehold Improvements	-	25.32	26.21	24.58	24.05	24.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.